Semi-solid matrix,
preservative free

Semi-solid matrix,
preservative free

MetP’s gel matrix Silcum

  • is the advanced gel drug delivery system for nasal application
  • offers unique retention
  • releases molecules from a drug depot at the nasal mucosa
  • contains no preservatives
  • is patent-protected

The efficiency of an elaborated carrier matrix

To have the agent efficiently and reliably delivered, it needs to be integrated into some form of a carrier. MetP has developed a gel matrix providing this function: a semi-solid oil-based formulation with bio-adhesive properties – matching perfectly with our mono-dose device Lecticula.

What the unique gel carrier formulation provides

  • matrix for a broad range of compounds (hydrophilic/ lipophilic)
  • targeted drug delivery to brain and spinal cord, reduction of systemic side effects
  • nose-to-brain delivery of biologics
  • promotion of mucosal adsorption by bioadhesion and spreading
  • control of release kinetics by innovative carrier system
  • increase of drug solubility
  • protection of drug from biological and/or chemical degradation
  • safe and convenient application for the patient
  • easy manufacture and easy scalable

Perfectly spread, highly bio-adhesive

Due to its excellent spreading properties, the gel matrix reaches and covers the mucosal areas which are important for resorption. In contrast to aqueous sprays, the gel matrix resists immediate mucociliary self-cleaning. Instead and without running off, the gel matrix properly adheres to the nasal mucosa.

Controlled release of drugs

While adhering to the nasal mucosa, the gel matrix forms an emulsion layer. This layer makes sure that the agent molecules pass into the blood circulation or the brain respectively.

Preservative free, monographed and safe excipients (FDA GRAS), no irritations

To have the agents safely stored in the gel matrix, no preservatives are necessary. Also, the gel matrix is essentially odorless and it is perfectly well tolerated as tests have shown.

Proven efficacy, long-term safety

The gel matrix has been developed to protect, carry and deliver a wide range of agents, devised to perfectly function with our MetP’s mono-dose device Lecticula. Of course, the gel matrix has been thoroughly tested, also for long-term safety. Being the core of our MetP’s technology, the gel matrix is patent-protected.

Easily modified for a broad range of agents

So far, the gel matrix has proven its efficacy with several agents. In all cases, the gel matrix was adapted to the demands of the specific agents. In combination with our mono-dose device Lecticula, it is possible to use our matrix for many other drug substances that are or could be most effectively applied via nose. Ask us.

Suitable for the nose-to-brain delivery of biologics for the treatment of neurological disorders

Biologics seem to be the future of medicine but there are huge challenges regarding a safe and effective delivery of these molecules to the brain. Silcum provides a strategy for direct and non-invasive route to the brain which can bypass the Blood-Brain-Barrier.

We have developed our gel matrix to incorporate many types of molecules.

The production of the gel matrix is a straightforward process and allows fast scale up possibilities. It is possible to use our matrix for many other drug substances, probably also yours.

Claudia Mattern, CSO
Udo Mattern, CEO
Phone +41-41-618 30 30
Email

Summary

After being applied by our mono-dose device Lecticula, the gel matrix bio-adhesively attaches to the nasal mucosa. Simultaneously it creates an emulsion layer and passes the agents completely through the nasal mucosa into the blood circulation or to the brain. MetP’s gel matrix has been developed to incorporate many types of molecules, and it is a proven effective carrier for numerous different agents. Read more about our MetP’s mono-dose applicator Lecticula or our pertaining filling machine Maxima.

Udo Mattern CEO and chairman MetP Pharma AG

«Our matrix formulation respects the anatomy of the nose, the mucociliary clearance of the nasal mucosa as well as the physico-chemical characteristics of the drug.»

Udo Mattern CEO and chairman MetP Pharma AG